Skip to content

Treasury Stock at other companies

BridgeBio Pharma logo
BridgeBio PharmaBBIO
$405.78M+25.5%
Royalty Pharma logo
Royalty PharmaRPRX
$2.71M+2.1%
United Therapeutics logo
United TherapeuticsUTHR
$5.44B+56.6%
Medpace Holdings, Inc. logo
Medpace Holdings, Inc.MEDP
$12.16M-0.6%
Johnson & Johnson logo
Johnson & JohnsonJNJ
$76.26B+0.5%
Tenet Healthcare logo
Tenet HealthcareTHC
$5.26B+35.2%

Other financials

Income statement

See full
Revenue$73.7M-86.4%
Operating income-$141.3M-137%
Net income-$132.7M-136%
EPS (diluted)-$0.93-134%

Balance sheet

See full
Cash & equivalents$188.5M+1.5%
Total debt$107.9M-5.6%
Total equity$614.0M-10.1%
Total assets$2.3B+44.2%

Cash flow

See full
Operating cash flow$84.4M-81.6%
CapEx$2.6M-51.6%
Free cash flow$81.9M-82.0%

Valuation

See full
Market cap$11.52B+402%
Enterprise value$11.44B+418%
P/S18.5×+14.3×

Profitability

See full
Operating margin-35.7%+63.6pp
Net margin-48.4%+240pp
FCF margin1.8%+0.9pp

Returns & leverage

See full
Return on equity-46.4%+341pp
Debt / equity0.2×0.0×
Current ratio6.2×+1.1×

Where this comes from

Reported directly by Arrowhead Research in its filing.

Tagged under the XBRL concept us-gaap:TreasuryStockCommonValue.

The official record: Arrowhead Research’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Arrowhead Research's treasury stock.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Arrowhead Research's treasury stock?
Arrowhead Research (ARWR) reported treasury stock of $53.19M in Q1 2026.
What does treasury stock mean?
The value of shares the company has bought back from the market and is holding itself.
How do you interpret treasury stock?
An increase indicates a share buyback program, while a decrease suggests the reissuance of shares for employee compensation or other corporate purposes.
How does treasury stock compare across companies?
Common in mature companies; less common in early-stage biotech firms that prioritize cash preservation for R&D.